Interstitial Lung Disease News

“Aggressive” combination therapy for gastroesophageal reflux disease improved survival among patients with systemic sclerosis and interstitial lung disease, according to data published in Arthritis Research & Therapy.

Enrollment in the phase 3 VALOR study evaluating brepocitinib for the treatment of dermatomyositis has been completed, Priovant Therapeutics announced in a press release.

Increased body surface area lowered the likelihood for nintedanib dose reduction/discontinuation among patients with fibrotic interstitial lung disease, according to results published in Respiratory Medicine.

Individuals living in medium/small metropolitan and rural areas had increased idiopathic pulmonary fibrosis-related mortality rates vs. those living in large metropolitan areas, according to results published in CHEST.

The risk for mortality was heightened among patients with idiopathic pulmonary fibrosis who experienced more deprivation and lived far from a hospital, according to results published in Respiratory Medicine.

In a study of patients with small cell lung cancer and idiopathic pulmonary fibrosis receiving carboplatin, etoposide and nintedanib, the primary endpoint was met, according to results published in Annals of the American Thoracic Society.

Doctors from across the world gathered at this year’s American Thoracic Society International Conference in San Diego to present research on various respiratory diseases and conditions.

SAN DIEGO — Six months before dying, patients with COPD and idiopathic pulmonary fibrosis vs. lung cancer had reduced odds for outpatient palliative care, according to a poster at the American Thoracic Society International Conference.

Among patients with idiopathic pulmonary fibrosis, 12-week bexotegrast was deemed well tolerated and may have an antifibrotic effect, according to results published in American Journal of Respiratory and Critical Care Medicine.

SAN DIEGO — Among patients with idiopathic pulmonary fibrosis, twice-daily buloxibutid for 36 weeks significantly improved FVC, according to research presented at the American Thoracic Society International Conference.